Key Highlights

  • Hydrix reported A$6.5 million of new MedTech and DefenceTech services contracts in its June 2026 quarterly update.
  • Total loan facilities of A$6.0 million are fully drawn, mostly from directors and related parties, maturing between 1 and 11 October 2026.
  • The entitlement offer announced on 18 May 2026 with a A$8.18 million target had raised A$5.2 million by the quarterly update.

Hydrix (ASX:HYD) is a product-development and engineering services group serving medical technology and, more recently, defence customers. It has been winning larger engineering contracts while relying on an equity raising and the conversion of related-party debt to stay funded. In its June 2026 quarterly update, released on 30 July 2026, the company reported A$6.5 million of new MedTech and DefenceTech services contracts, alongside a funding runway of 1.81 quarters in its Appendix 4C.

Business and recent contracts

Hydrix designs and builds devices, software and embedded electronics for clients and runs a small venture arm. Its 28 August 2026 chairman's letter put total FY26 sales contract wins at A$11.7 million, with about A$4.0 million more since year end. Named wins include a A$2.5 million contract with SynCardia Systems for the Emperor Total Artificial Heart, a A$3.4 million stage for Remedy Robotics' N1 endovascular robotics platform, announced on 20 July 2026, and a A$1.2 million counter-drone payload subsystem stage for NIOA Group.

Contract wins differ from recognised revenue. Group revenue for the June quarter was A$2.2 million, and the company said active client programmes exceeded 15 with an estimated aggregate value above A$37 million. That programme value is a management estimate, and revenue depends on delivery milestones. In May 2026 Hydrix also established Hydrix Defence, a subsidiary set up to pursue technology acquisition, licensing and development.

Cash flow and funding

Customer receipts were A$1.9 million for the June quarter and A$11.0 million for the year to date, while net operating cash outflow was A$1.6 million. Hydrix attributed a cash operating loss of A$0.9 million to a temporary funding-related pause in the SynCardia programme and a delayed receivable. Cash at 30 June 2026 was about A$3.0 million, after a net financing inflow of A$4.4 million.

Total loan facilities of A$6.0 million are fully drawn, mostly from directors and related parties, with maturities between 1 and 11 October 2026. The company says debt conversion commitments of A$5.1 million are intended to remove those repayments, subject to final raise amounts and a 20 per cent ownership threshold. It has not yet reported the final status of those conversions.

Dilution

The accelerated renounceable entitlement offer, announced on 18 May 2026 with a A$8.18 million target, had raised A$5.2 million by the quarterly update, which described a A$2.9 million retail shortfall bookbuild as open until 4 September 2026. An earlier announcement dated 16 June was titled as completion of the retail shortfall bookbuild. In addition, 1,044,580,462 quoted HYDOC options with a A$0.01 exercise price and a 30 June 2029 expiry were on issue at 18 June 2026. Debt conversion and option exercise would both add shares.

What to Watch

The board has stated that operations are expected to continue based on completion of the entitlement offer and current trading assumptions, which underlines the reliance on funding outcomes. Other risks include concentration on a small number of large clients and programme pauses outside Hydrix's control. The chairman also said uncertain reimbursement pathways for medical products, such as the Implicity remote cardiac monitoring platform, affect sales timelines. The October 2026 loan maturities and the outcome of the debt conversions are the near-term items to follow.